

# Want to be a part of history?



Here are five of the best reasons why we at Project Evolution think this is a once-in-a-lifetime opportunity.

[PARTNERCOMPANY.com](http://PARTNERCOMPANY.com)



1

## Industry-Leader in Genomic Medicine.

PARTNER COMPANY is a genomic medicine company conducting research & development across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation to treat underlying genetic causes of disease. PARTNER COMPANY has a robust clinical pipeline comprising a balance of 17 wholly-owned and partnered programs across an array of indications, including one Phase 3 trial for X as well as four assets that are in Phase 1/2; click [HERE](#) to learn more. Also, check out PARTNER COMPANY's top ten marks for Gene Online's top 10 Gene Therapy Companies in 2021 [HERE](#).

2

## World-Class Management Team and Board of Directors.

PARTNER COMPANY's leadership includes many distinguished Industry leaders with a diverse range of experience and expertise. Including many demonstrated industry leaders who have experience progressing product candidates into clinical development to commercialization. Click [HERE](#) to learn more.

3

## Manufacturing Capacity and Capabilities

PARTNER COMPANY is nearing completion of its buildout of an XX,000 sf state-of-the-art cGMP manufacturing facility at the new HQ on the West Coast. When complete the facility will provide clinical and commercial-scale manufacturing capacity for Cell and Gene Therapy programs. The Company has also initiated the buildout of a cell therapy manufacturing facility in Europe. PARTNER COMPANY's manufacturing strategy includes in-house capabilities and the use of CDMOs, including a long-established relationship with XXXXX. To learn more about PARTNER COMPANY's decision to build, click [HERE](#).

4

## Significant Market Cap and Cash Position

PARTNER COMPANY is a publically traded company on the NASDAQ (XXXX). The organization has a market cap that exceeds \$1.5bn. At the end of 2021, PARTNER COMPANY had \$692M cash and cash equivalents on the books, compared to \$384.3M at the same time the year prior.

5

## Building Value with Pharmaceutical Partnerships

PARTNER COMPANY values partnerships with companies that share its mission of translating ground-breaking science into genomic medicines that transform patients' lives. The organization has deep experience partnering with pioneering organizations such as Big Pharma 1, Big Pharma 2, Big Pharma 3, Big Pharma 4, and recently inked collaborative deals with Big Pharma 5 and Big Pharma 6. Click [HERE](#) to learn more.

### New HQ with Integrated R&D GMP Facility



### High-value Pharmaceutical Partnerships

